Selecting Treatments During an Infectious Disease Pandemic: Chasing the Evidence.

In their article, Mehta and colleagues describe temporal trends in the use of hydroxychloroquine, remdesivir, and dexamethasone for the treatment of COVID-19 in patients hospitalized in the United States over a 13-month period beginning in February 2020. The editorialists discuss the findings and lessons learned from COVID-19 that will improve how we assess and disseminate emerging data leading to efficient, evidence-based implementation (or deimplementation) of treatment.